[Treatment options and limitations in the management of myelofibrosis].

Abstract excerpt

Primary myelofibrosis has the worst outcome among classical chronic myeloproliferative neoplasms. The past decade has brought numerous discoveries elucidating the role of proliferative mutations in disease pathogenesis. Mutations of the genes JAK2, MPL and CALR are present in about 90 percent of all primary myelofibrosis cases. The prognosis of myelofibrosis is considered heterogeneous, the expected survival of...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Prognosis
• Share to CALR gene
• Share to JAK2 gene